Nerve stimulation for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests whether a gentle nerve stimulation therapy can improve symptoms and quality of life for people with moderate pulmonary arterial hypertension (PAH). It is for adults whose PAH is stable but still causes mild to moderate trouble with daily activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Group 1 pulmonary arterial hypertension (PAH).
- Your PAH symptoms put you at WHO functional class II or III (mild to moderate symptoms during daily activity).
- You are able to walk and not wheelchair-bound.
- You do not have active cancer or a life expectancy less than 3 to 6 months.
- You are comfortable speaking English (Spanish-speaking patients are not included in this study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device that uses a catheter to deliver energy to nerves around the pulmonary arteries, aiming to reduce high blood pressure in the lungs caused by left heart failure. It is for people with ongoing heart failure symptoms despite optimal medications.
This study tests whether a special exercise training program can help people with pulmonary arterial hypertension (PAH) feel better and stay stable. If you have mild-to-moderate PAH and are on stable medication, you may be able to join.
This study tracks how well a procedure called PADN works for people with pulmonary artery hypertension (PAH) in real-life medical settings. PADN is a minimally invasive treatment that targets nerves around the lungs to help lower blood pressure in the arteries.
This trial tests a new treatment that uses a device to calm overactive nerves in the lung's blood vessels. It is for heart failure patients who also have high blood pressure in their lungs, to see if it can help them breathe easier and feel better.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.